Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial-Reference-Cited by-同舟云学术

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

Published:2009-10 Issue:9698 Volume:374 Page:1331-1338
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Katsumata Noriyuki,Yasuda Makoto,Takahashi Fumiaki,Isonishi Seiji,Jobo Toshiko,Aoki Daisuke,Tsuda Hiroshi,Sugiyama Toru,Kodama Shoji,Kimura Eizo,Ochiai Kazunori,Noda Kiichiro

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

General Medicine

Reference26 articles.

1. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004);du Bois;Ann Oncol,2005

2. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup;Bookman;J Clin Oncol,2009

3. Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens

4. Hoskins PJ, Vergote I, Stuart G, et al. A phase III trial of cisplatin plus topotecan followed by paclitaxel plus carboplatin versus standard carboplatin plus paclitaxel as first-line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer (EOC) (OV.16). A Gynecologic Cancer Intergroup Study of the NCIC CTG, EORTC GCG, and GEICO. 2008 ASCO Annual Meeting; Chicago, IL USA; May 30–June 3, 2008. Abstract LBA5505.

5. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines;Lopes;Cancer Chemother Pharmacol,1993

Cited by 643 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multicenter retrospective study to assess feasibility, safety and efficacy of first-line carboplatin-paclitaxel versus carboplatin monotherapy in a frail, elderly epithelial ovarian cancer population;International Journal of Gynecologic Cancer;2024-09-03

2. British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-09

3. Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial;Med;2024-08

4. A single institutional clinical outcome for stages III and IV ovarian cancer patients treated with dose‐dense TC therapy in the frontline or first platinum‐sensitive relapse setting;Journal of Obstetrics and Gynaecology Research;2024-07-02

5. Artificial Intelligence-Based Histopathological Subtyping of High-Grade Serous Ovarian Cancer;The American Journal of Pathology;2024-07